Epilepsy Research
Epilepsy is a group of neurological conditions consisting of recurrent, usually unprovoked epileptic seizures. Epileptic seizures have recently been defined as "a transient occurrence of signs and/or symptoms due to abnormal, excessive or synchronous neuronal activity in the brain". Epilepsy is one of the most common disorders of the brain, with one in 10 people suffering at least one seizure in their lifetime. There are over 40 different types of epilepsy, each of which presents with its own unique combination of seizure type, typical age of onset, EEG findings, treatment, and prognosis.
Epilepsy Research Products Targets
- NHE (3)
- Monocarboxylate Transporter (3)
- VEGFR (16)
- FGFR (5)
- Voltage-gated Sodium (NaV) Channel (30)
- Voltage-gated Potassium (KV) Channel (38)
- Voltage-gated Calcium Channel (CaV) (38)
- Others (13)
- Epithelial Sodium Channel (3)
- STIM-Orai Channel (4)
- Ryanodine Receptor (6)
- Glutamate (Metabotropic) Group III Receptor (26)
- Glutamate (Metabotropic) Group II Receptor (33)
- Glutamate (Metabotropic) Group I Receptor (54)
- AMPA Receptor (45)
- GABAA-ρ Receptor (8)
- GABAA Receptor (66)
- NMDA Receptor (87)
- Kainate Receptor (22)
- IP3 Receptor (2)
- Gap Channel (7)
- Trk Receptor (13)
- Acid-Sensing Ion Channel (3)
- Calcium-Activated Potassium (KCa) Channel (19)
- Inward Rectifier Potassium (Kir) Channel (21)
- Sodium and Potassium ATPase (3)
- KCC2 (1)
- H+-ATPase (3)
- H+,K+-ATPase (4)
- Chloride Channel (17)
- NCX (5)
- Ca2+-ATPase (7)
- NKCC (2)
- Cytokine (15)
Products for Epilepsy Research - Page 28
- Cat.No. Product Name Information/Activity
-
BCC7753
DL-AP5 Sodium salt
1303993-72-7
-
BCC6553
D-AP5
D-AP5 is a NMDA receptor antagonist.
-
BCC6552
DL-AP5
76326-31-3
-
BCC6554
L-AP5
79055-67-7
-
BCC6551
DL-AP7
78966-69-5
-
BCC6631
Arcaine sulfate
14923-17-2
-
BCC6602
(R)-4-Carboxyphenylglycine
134052-68-9
-
BCC7078
CGP 37849
CGP 37849 is a potent, competitive and orally active N-methyl-D-aspartate (NMDA) receptor antagonist. CGP 37849 is an anticonvulsant in rodents and has antidepressant and anxiolytic-like effects.
-
BCC7053
CGP 39551
127910-32-1
-
BCC7087
CGP 78608 hydrochloride
CGP 78608 hydrochloride is a highly potent and selective antagonist at the glycine-binding site of the NMDA receptor, with an IC50 of 6 nM. CGP 78608 acts as a potentiator of GluN1/GluN3A-mediated glycine currents, with an estimated EC50 in the low nM range (26.3 nM). Anticonvulsant activity.


